Could the Next GLP-1-Style Boom Come from Wound Care?

The Bottom Line: GLP-1 medicines reshaped obesity care by offering a biological alternative to surgery. MediWound (NASDAQ: MDWD) is applying that same idea to wound care. Its enzyme-based treatments can remove dead tissue without surgery, with NexoBrid® already approved in 40+ locations around the globe and EscharEx® showing impressive Phase 2 results in chronic wounds. With strong partners, a major manufacturing expansion, and cash to reach key milestones, MediWound may be one of biotech’s most overlooked growth stories.

As biology replaces surgery across more areas of medicine, one under the radar biotech player could be leading the next transformation.

When GLP-1 drugs like Ozempic and Wegovy hit the market, they didn’t just change how doctors treat obesity – they changed how investors think about medicine itself.
A single biologic began to displace a significant share of invasive weight-loss surgeries, created an entirely new category of care, and unleashed one of the fastest value-creation cycles in biotech history.

Now, in a very different corner of healthcare, MediWound (NASDAQ: MDWD) may be setting up a similar kind of shift. The company is using enzymatic therapeutics to reduce the need for surgical procedures in wound and burn care – turning a centuries-old surgical routine into a precise, biology-based treatment.

From Scalpel to Science

For decades, surgeons have had to physically cut away dead tissue – a process called debridement – to treat severe burns or chronic wounds. It’s painful, costly, and often imprecise. MediWound’s solution removes the scalpel from the equation.

Its technology uses enzymes derived from natural sources that selectively dissolve dead tissue while sparing healthy skin – a biochemical cleanup that happens without surgery.

The company’s FDA-approved product, NexoBrid®, is already being used in more than 40 countries, including the U.S. and EU. It can prepare burn wounds for grafting within hours instead of days, reducing or sometimes avoiding the need for surgery. Hospitals report shorter stays and lower costs, and the therapy’s uptake is accelerating fast. MediWound has completed commissioning of its expanded facility, which will expan its production capacity six fold, and is expected to reach full operational readiness by year-end 2025 to keep up with global demand.

Next in line is EscharEx®, the company’s late-stage program for chronic wounds such as diabetic and venous leg ulcers – a vast and costly area of unmet need. In a Phase 2 clinical study, EscharEx achieved 63 percent complete debridement in two weeks, compared with 0 percent in the comparator SANTYL® group, and cut the median time to debridement to nine days (p < 0.05).

If its ongoing Phase 3 trial confirms those results, EscharEx could enter a U.S. market worth over $2.5 billion, with a recent market access study estimating potential peak sales of $831 million.

The GLP-1 Parallel – Biology Over Surgery

The comparison to GLP-1 drugs isn’t about metabolism – it’s about a structural revolution in medicine.

GLP-1s transformed metabolic care by proving that a single biologic approach could outperform surgery for many patients, delivering better outcomes at lower cost. MediWound’s platform applies that same principle to wound care:

Replace surgical excision with a biologic mechanism
Improve outcomes while reducing the total cost of care
Scale globally once regulatory and manufacturing barriers fall

Both stories are about precision biology displacing invasive procedures – and both open entirely new commercial markets in the process.

Strategic Momentum and Scale

MediWound’s trajectory mirrors the early inflection point of the GLP-1 revolution – small at first, but increasingly validated by the biggest names in healthcare.

The company has partnered with leading wound-care players including Solventum (3M spinoff), Mölnlycke, Essity, MiMedx, and Kerecis (Coloplast). In 2024, it raised $25 million in a strategic investment led by Mölnlycke, followed by a €2.5 million grant from the European Innovation Council to advance EscharEx in the diabetic foot ulcer (DFU) program. In September 2025, MediWound strengthened its position further with a $30 million registered direct offering, extending its cash runway well beyond key clinical milestones.

As of September 30, 2025, MediWound reported $60 million in cash and equivalents and no debt. The global VALUE Phase 3 trial for EscharEx began enrolling in February 2025, with an interim analysis expected once two-thirds of patients complete treatment in mid-2026 and expects to initiate the DFU clinical trial in the second half of 2026.

Combined with steady revenue growth from NexoBrid – already stockpiled by the U.S. government through BARDA, the same agency that funds national defense medical countermeasures – the company appears well positioned to execute at scale.

A Shift Investors Are Starting to Notice

GLP-1s showed what happens when a biologic turns a niche treatment into a mass-market paradigm shift. The same underlying forces – biologic precision, lower costs, and global scalability – are now emerging in wound care.

MediWound’s enzymes don’t just treat wounds differently; they seem to reduce the need for surgery and, in many cases, provide a non-surgical alternative. History shows that when data, manufacturing, and partnerships align, these biological shifts tend to move fast – and the companies behind them rarely stay under the radar for long.

The Bottom Line

GLP-1 drugs redefined metabolic medicine by proving that a single biologic could reshape an entire industry. MediWound may be following that same playbook in a different arena – transforming wound care from a surgical craft into a precise, biology-driven science.

With an approved product in burns, a Phase 3 program in chronic wounds, expanding global capacity, and backing from industry leaders and public agencies, MediWound sits squarely at the intersection of biology, scalability, and unmet clinical need – the same ingredients that turned GLP-1s from niche science into a worldwide phenomenon.

For investors watching the next wave of biotech disruption, wound care may be more than a medical story – it could be the next GLP-1-style breakout